TOPICS

Tag: ixekizumab

Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review

J Clin Aesthet Dermatol. 2021;14(6):55–59. by Donovan G. Kearns, BA; Shelley Uppal, MD; Vipawee S. Chat, BA; and Jashin J. Wu, MD Mr. Kearns is with Loma Linda University School of Medicine in Loma Linda, California. Dr. Uppal is with Albany Medical College School of Medicine in Albany, New York. Ms. Chat is with the

CONTINUE READING »

The Psoriasis Decision Tree

J Clin Aesthet Dermatol. 2021;14(4):14–22. by George Monks, MD; Ryan Rivera-Oyola, MS; Mark Lebwohl, MD Dr. Monks is with the Department of Dermatology, University of Oklahoma College of Medicine in Oklahoma City, Oklahoma. Mr. Rovera-Oyola and Dr. Lebwohl are with the Department of Dermatology, Icahn School of Medicine at Mt. Sinai Hospital in New York,

CONTINUE READING »

Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study

J Clin Aesthet Dermatol. 2020;13(10):18–22 by Luis Puig, MD, PhD; Baojin Zhu, PhD; Russel Burge, PhD, MA; David Shrom, PhD; Yan Dong, PhD; Wei Shen, PhD; Lotus Mallbris, MD, PhD; and Kristian Reich, PhD Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain. Drs. Zhu,

CONTINUE READING »